SCHEDULE OF PHARMACEUTICAL BENEFITS EFFECTIVE 1 NOVEMBER 2026
ERRATUM

This erratum advises changes for 8 octreotide modified release items for 1 November 2026. The full restrictions for these items are outlined below.

Highly Specialised Drugs Program (Private Hospital)

OCTREOTIDE

Authority Required (STREAMLINED)

19543

Functional carcinoid tumour

Clinical criteria:

- Patient must have achieved symptom control on octreotide immediate release injections, **AND**
- The treatment must cease if there is failure to produce a clinically significant reduction in the frequency and severity of symptoms after 3 months therapy at a dose of 30 mg every 28 days and having allowed adequate rescue therapy with octreotide immediate release injections.

Treatment criteria:

- Must be treated by a specialist medical practitioner; **OR**
- Must be treated by a non-specialist medical practitioner where the prescription continues existing therapy with this medicine; **OR**
- Must be treated by a nurse practitioner where both of the following are occurring: (i) patient care is being shared with a specialist medical practitioner, (ii) the prescription continues existing therapy with this medicine.

Dosage and tolerance to the drug should be assessed regularly and the dosage should be titrated slowly downwards to determine the minimum effective dose.

Authority Required (STREAMLINED)

19544

Vasoactive intestinal peptide secreting tumour (VIPoma)

Clinical criteria:

- Patient must have achieved symptom control on octreotide immediate release injections, **AND**
- The treatment must cease if there is failure to produce a clinically significant reduction in the frequency and severity of symptoms after 3 months therapy at a dose of 30 mg every 28 days and having allowed adequate rescue therapy with octreotide immediate release injections.

Treatment criteria:

- Must be treated by a specialist medical practitioner; **OR**
- Must be treated by a non-specialist medical practitioner where the prescription continues existing therapy with this medicine; **OR**
- Must be treated by a nurse practitioner where both of the following are occurring: (i) patient care is being shared with a specialist medical practitioner, (ii) the prescription continues existing therapy with this medicine.

Dosage and tolerance to the drug should be assessed regularly and the dosage should be titrated slowly downwards to determine the minimum effective dose.

octreotide 10 mg modified release injection [1 vial] (&) inert substance diluent [2 mL syringe], 1 pack

15629N	Max.Qty Packs	No. of Rpts	Premium $	DPMQ $	Brand Name and Manufacturer
NP	2	5	0.00	*829.96	Sandostatin LAR [NV]

octreotide 20 mg modified release injection [1 vial] (&) inert substance diluent [2 mL syringe], 1 pack

15649P	Max.Qty Packs	No. of Rpts	Premium $	DPMQ $	Brand Name and Manufacturer
NP	2	5	0.00	*1099.86	Sandostatin LAR [NV]

octreotide 30 mg modified release injection [1 vial] (&) inert substance diluent [2 mL syringe], 1 pack

15639D	Max.Qty Packs	No. of Rpts	Premium $	DPMQ $	Brand Name and Manufacturer
NP	2	5	0.00	*1256.56	Sandostatin LAR [NV]

OCTREOTIDE

Note No increase in the maximum quantity or number of units may be authorised.
Note No increase in the maximum number of repeats may be authorised.

Authority Required (STREAMLINED)

19538

Non-functional gastroenteropancreatic neuroendocrine tumour (GEP-NET)

Clinical criteria:

- The condition must be unresectable locally advanced disease or metastatic disease, **AND**
- The condition must be World Health Organisation (WHO) grade 1 or 2, **AND**
- The treatment must be either: (i) as monotherapy; (ii) in combination with cabozantinib.

Population criteria:

- Patient must be at least 18 years of age.

Treatment criteria:

- Must be treated by a specialist medical practitioner; **OR**
- Must be treated by a non-specialist medical practitioner where the prescription continues existing therapy with this medicine; **OR**
- Must be treated by a nurse practitioner where both of the following are occurring: (i) patient care is being shared with a specialist medical practitioner, (ii) the prescription continues existing therapy with this medicine.

WHO grade 1 of GEP-NET is defined as a mitotic count (10HPF) of less than 2 and Ki-67 index (%) of less than or equal to 2.

WHO grade 2 of GEP-NET is defined as a mitotic count (10HPF) of 2-20 and Ki-67 index (%) of 3-20.

octreotide 30 mg modified release injection [1 vial] (&) inert substance diluent [2 mL syringe], 1 pack

11894B	Max.Qty Packs	No. of Rpts	Premium $	DPMQ $	Brand Name and Manufacturer
NP	2	5	0.00	*1256.56	Sandostatin LAR [NV]

Highly Specialised Drugs Program (Public Hospital)

OCTREOTIDE

Authority Required (STREAMLINED)

19539

Functional carcinoid tumour

Clinical criteria:

- Patient must have achieved symptom control on octreotide immediate release injections, **AND**
- The treatment must cease if there is failure to produce a clinically significant reduction in the frequency and severity of symptoms after 3 months therapy at a dose of 30 mg every 28 days and having allowed adequate rescue therapy with octreotide immediate release injections.

Treatment criteria:

- Must be treated by a specialist medical practitioner; **OR**
- Must be treated by a non-specialist medical practitioner where the prescription continues existing therapy with this medicine; **OR**
- Must be treated by a nurse practitioner where both of the following are occurring: (i) patient care is being shared with a specialist medical practitioner, (ii) the prescription continues existing therapy with this medicine.

Dosage and tolerance to the drug should be assessed regularly and the dosage should be titrated slowly downwards to determine the minimum effective dose.

Authority Required (STREAMLINED)

19549

Vasoactive intestinal peptide secreting tumour (VIPoma)

Clinical criteria:

- Patient must have achieved symptom control on octreotide immediate release injections, **AND**
- The treatment must cease if there is failure to produce a clinically significant reduction in the frequency and severity of symptoms after 3 months therapy at a dose of 30 mg every 28 days and having allowed adequate rescue therapy with octreotide immediate release injections.

Treatment criteria:

- Must be treated by a specialist medical practitioner; **OR**
- Must be treated by a non-specialist medical practitioner where the prescription continues existing therapy with this medicine; **OR**
- Must be treated by a nurse practitioner where both of the following are occurring: (i) patient care is being shared with a specialist medical practitioner, (ii) the prescription continues existing therapy with this medicine.

Dosage and tolerance to the drug should be assessed regularly and the dosage should be titrated slowly downwards to determine the minimum effective dose.

octreotide 10 mg modified release injection [1 vial] (&) inert substance diluent [2 mL syringe], 1 pack

15627L	Max.Qty Packs	No. of Rpts	Premium $	DPMQ $	Brand Name and Manufacturer
NP	2	5	0.00	*789.16	Sandostatin LAR [NV]

octreotide 20 mg modified release injection [1 vial] (&) inert substance diluent [2 mL syringe], 1 pack

15658D	Max.Qty Packs	No. of Rpts	Premium $	DPMQ $	Brand Name and Manufacturer
NP	2	5	0.00	*1050.62	Sandostatin LAR [NV]

octreotide 30 mg modified release injection [1 vial] (&) inert substance diluent [2 mL syringe], 1 pack

15647M	Max.Qty Packs	No. of Rpts	Premium $	DPMQ $	Brand Name and Manufacturer
NP	2	5	0.00	*1207.32	Sandostatin LAR [NV]
				[a]	Sandostatin 0.5 [NV]

OCTREOTIDE

Note No increase in the maximum quantity or number of units may be authorised.
Note No increase in the maximum number of repeats may be authorised.

Authority Required (STREAMLINED)

19562

Non-functional gastroenteropancreatic neuroendocrine tumour (GEP-NET)

Clinical criteria:

- The condition must be unresectable locally advanced disease or metastatic disease, **AND**
- The condition must be World Health Organisation (WHO) grade 1 or 2, **AND**
- The treatment must be either: (i) as monotherapy; (ii) in combination with cabozantinib.

Population criteria:

- Patient must be at least 18 years of age.

Treatment criteria:

- Must be treated by a specialist medical practitioner; **OR**
- Must be treated by a non-specialist medical practitioner where the prescription continues existing therapy with this medicine; **OR**
- Must be treated by a nurse practitioner where both of the following are occurring: (i) patient care is being shared with a specialist medical practitioner, (ii) the prescription continues existing therapy with this medicine.

WHO grade 1 of GEP-NET is defined as a mitotic count (10HPF) of less than 2 and Ki-67 index (%) of less than or equal to 2.

WHO grade 2 of GEP-NET is defined as a mitotic count (10HPF) of 2-20 and Ki-67 index (%) of 3-20.

octreotide 30 mg modified release injection [1 vial] (&) inert substance diluent [2 mL syringe], 1 pack

11893Y	Max.Qty Packs	No. of Rpts	Premium $	DPMQ $	Brand Name and Manufacturer
NP	2	5	0.00	*1207.32	Sandostatin LAR [NV]